A series of 2′-deoxy and novel 2′-O-methyl and 2′-O-(2-methoxyethyl) (2′-MOE) oligonucleotides with internucleotide methanesulfonyl (mesyl, μ) or 1-butanesulfonyl (busyl, β) phosphoramidate groups has been synthesized for evaluation as potential splice-switching oligonucleotides. Evaluation of their splice-switching activity in spinal muscular atrophy patient-derived fibroblasts revealed no significant difference in splice-switching efficacy between 2′-MOE mesyl oligonucleotide and the corresponding phosphorothioate (nusinersen). Yet, a survival study with model neonatal mice has shown the antisense 2′-MOE mesyl oligonucleotide to be inferior to nusinersen at the highest dose of 40 mg/kg. A reason for their lower activity in vivo as ascertained by cellular uptake study by fluorescent confocal microscopy in HEK293 cell line could possibly be ascribed to compromised endosomal release and/or nuclear uptake of the 2′-OMe or 2′-MOE μ- and β-oligonucleotides compared to their phosphorothioate analog.
Get full access to this article
View all access options for this article.
References
1.
Crooke ST. (2017). Molecular mechanisms of antisense oligonucleotides. Nucleic Acid Ther, 27:70–77.
2.
ShenX and CoreyDR. (2018). Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs. Nucleic Acids Res, 46:1584–1600.
3.
Smith CIE and ZainR. (2019). Therapeutic oligonucleotides: state of the art. Annu Rev Pharmacol Toxicol, 59:605–630.
4.
EversMM, ToonenLJA and van Roon-MomWMC. (2015). Antisense oligonucleotides in therapy for neurodegenerative disorders. Adv Drug Deliv Rev, 87:90–103.
5.
GaitMJ, ArzumanovAA, McCloreyG, GodfreyC, BettsC, HammondS and WoodMJA. (2019). Cell-penetrating peptide conjugates of steric blocking oligonucleotides as therapeutics for neuromuscular diseases from a historical perspective to current prospects of treatment. Nucleic Acid Ther, 29:1–12.
6.
BennettCF, BakerBF, PhamN, Swayze E and GearyRS. (2017). Pharmacology of antisense drugs. Annu Rev Pharmacol Toxicol, 57:81–105.
7.
CastanottoD and SteinCA. (2014). Antisense oligonucleotides in cancer. Curr Opin Oncol, 26:584–589.
8.
WagnerA, BockCT, FechnerH and KurreckJ. (2015). Application of modified antisense oligonucleotides and siRNAs as antiviral drugs. Future Med Chem, 7:1637–1642.
9.
HegartyJP and StewartDB, Sr. (2018). Advances in therapeutic bacterial antisense biotechnology. Appl Microbiol Biotechnol, 102:1055–1065.
10.
ShimoT, MaruyamaR and YokotaT. (2018). Designing effective antisense oligonucleotides for exon skipping. Methods Mol Biol, 1687:143–155.
Aartsma-RusA, StraubV, HemmingsR, HaasM, Schlosser-WeberC, Stoyanova-BeninskaV, MercuriE, MuntoniF, SepodesB, VroomE and BalabanovP. (2017). Development of exon skipping therapies for Duchenne muscular dystrophy: a critical review and a perspective on the outstanding issues. Nucleic Acid Ther, 27:251–259.
13.
HammondSM, AbendrothF, GaitMJ and WoodMJA. (2019). Evaluation of cell-penetrating peptide delivery of antisense oligonucleotides for therapeutic efficacy in spinal muscular atrophy. Methods Mol Biol, 2036:221–236.
14.
Aartsma-RusA and KriegAM. (2017). FDA approves eteplirsen for Duchenne muscular dystrophy: the next chapter in the Eteplirsen Saga. Nucleic Acid Ther, 27:1–3.
15.
He YA. (2020). Golodirsen: first approval. Drugs, 80:329–333.
16.
Aartsma-RusA. (2017). FDA approval of nusinersen for spinal muscular atrophy makes 2016 the year of splice modulating oligonucleotides. Nucleic Acid Ther, 2:67–69.
17.
LefebvreS, BurglenL, ReboulletS, ClermontO, BurletP, ViolletL, BenichouB, CruaudC, MillasseauP, et al. (1995). Identification and characterization of a spinal muscular atrophy-determining gene. Cell, 80:155–165.
18.
WirthB. (2000). An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA). Hum Mutat, 15:228–237.
19.
CartegniL and KrainerAR. (2002). Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1. Nat Genet, 30:377–384.
20.
KashimaT and ManleyJL. (2003). A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophy. Nat Genet, 34:460–463.
21.
LorsonCL, HahnenE, AndrophyEJ and WirthB. (1999). A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci U S A, 96:6307–6311.
22.
MonaniUR, LorsonCL, ParsonsDW, PriorTW, AndrophyEJ, BurghesAH and McPhersonJD. (1999). A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum Mol Genet, 8:1177–1183.
23.
LeTT, PhamLT, ButchbachME, ZhangHL, MonaniUR, CoovertDD, GavrilinaTO, XingL, BassellGJ and BurghesAH. (2005). SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN. Hum Mol Genet, 14:845–857.
24.
HuaY, VickersTA, BakerBF, BennettCF and Krainer.AR (2007). Enhancement of SMN2 exon 7 inclusion by antisense oligonucleotides targeting the exon. PLoS Biol, 5:e73.
SinghNK, SinghNN, AndrophyEJ and SinghRN. (2006). Splicing of a critical exon of human survival motor neuron is regulated by a unique silencer element located in the last intron. Mol Cell Biol, 26:1333–1346.
27.
FinkelRS, MercuriE, DarrasBT, ConnollyAM, KuntzNL, KirschnerJ, ChiribogaCA, SaitoK, ServaisL, et al. (2017). Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med, 377:1723–1732.
28.
StolteB, TotzeckA, KizinaK, BolzS, PietruckL, MönninghoffC, GuberinaN, OldenburgD, ForstingM, KleinschnitzC and Hagenacker.T (2018). Feasibility and safety of intrathecal treatment with nusinersen in adult patients with spinal muscular atrophy. Ther Adv Neurol Disord, 11:1756286418803246.
29.
WursterCD, WinterB, WollinskyK, LudolphAC, UzelacZ, WitzelS, SchockeM, SchneiderR and KocakT. (2019). Intrathecal administration of nusinersen in adolescent and adult SMA type 2 and 3 patients. J Neurol, 266:183–194.
GearyRS, NorrisD, YuR and BennettCF. (2015). Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv Drug Deliv Rev, 87:46–51.
32.
CrookeST, WangS, VickersTA, ShenW and LiangXH. (2017). Cellular uptake and trafficking of antisense oligonucleotides. Nat Biotechnol, 35:230–237.
33.
HagedornPH, YakimovV, OttosenS, KammlerS, NielsenNF, HøgAM, HedtjärnM, MeldgaardM, MøllerMR, et al. (2013). Hepatotoxic potential of therapeutic oligonucleotides can be predicted from their sequence and modification pattern. Nucleic Acid Ther, 23:302–310.
34.
ShenW, De HoyosCL, SunH, VickersTA, LiangXH and CrookeST. (2018). Acute hepatotoxicity of 2′ fluoro-modified 5-10-5 gapmer phosphorothioate oligonucleotides in mice correlates with intracellular protein binding and the loss of DBHS proteins. Nucleic Acids Res, 46:2204–2217.
35.
HenrySP, GiclasPC, LeedsJ, PangburnM, AulettaC, LevinAA and KornbrustDJ. (1997). Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action. J Pharmacol Exp Ther, 281:810–816.
36.
JasonTL, KoropatnickJ and BergRW. (2004). Toxicology of antisense therapeutics. Toxicol Appl Pharmacol, 201:66–83.
37.
SteinCA and CastanottoD. (2017). FDA-approved oligonucleotide therapies. Mol Ther, 25:1069–1075.
38.
van PuttenM, Tanganyika-de WinterC, BosgraS and Aartsma-RusA. (2019). Nonclinical exon skipping studies with 2′-O-methyl phosphorothioate antisense oligonucleotides in mdx and mdx-utrn−/− mice inspired by clinical trial results. Nucleic Acid Ther, 29:92–103.
39.
KhvorovaA and WattsJK. (2017). The chemical evolution of oligonucleotide therapies of clinical utility. Nat Biotechnol, 35:238–248.
40.
ShenW, De HoyosCL, MigawaMT, VickersTA, SunH, LowA, BellTA, 3rd, RahdarM, MukhopadhyayS, et al. (2019). Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index. Nat Biotechnol, 37:640–650.
41.
SivaK, Covello G and DentiMA. (2014). Exon-skipping antisense oligonucleotides to correct missplicing in neurogenetic diseases. Nucleic Acid Ther, 24:69–86.
42.
MiroshnichenkoSK, PatutinaOA, BurakovaEA, ChelobanovBP, FokinaAA, VlassovVV, AltmanS, ZenkovaMA and StetsenkoDA. (2019). Mesyl phosphoramidate antisense oligonucleotides as an alternative to phosphorothioates: improved biochemical and biological properties. Proc Natl Acad Sci U S A, 116:1229–1234.
43.
BurakovaEA, DerzhalovaAS, ChelobanovaBP, FokinaAA and StetsenkoDA. (2019). New oligodeoxynucleotide derivatives containing N-(sulfonyl)-phosphoramide groups. Russ J Bioorg Chem, 45:662–668.
44.
LimaWF and CrookeST. (1997). Binding affinity and specificity of Escherichia coli RNase H1: impact on the kinetics of catalysis of antisense oligonucleotide-RNA hybrids. Biochemistry, 36:390–398.
FarzanVM, UlashchikEA, Martynenko-MakaevYV, KvachMV, AparinIO, BrylevVA, PrikazchikovaTA, MaklakovaSY, MajougaAG, et al. (2017). Automated solid-phase click synthesis of oligonucleotide conjugates: from small molecules to diverse N-acetylgalactosamine clusters. Bioconjug Chem, 28:2599–2607.
47.
HoncharenkoM, HoncharenkoD and StrömbergR. (2019). Efficient conjugation to phosphorothioate oligonucleotides by Cu-catalyzed Huisgen 1,3-dipolar cycloaddition. Bioconjug Chem, 30:1622–1628.
48.
RamakersC, RuijterJM, Lekanne DeprezRH and MoormanAFM. (2003). Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data. Neurosci Lett, 339:62–66.
49.
RuijterJM, RamakersC, HoogaarsWMH, KarlenY, BakkerO, van den HoffMJB and Moorman.AFM (2009). Amplification efficiency: linking baseline and bias in the analysis of quantitative PCR data. Nucleic Acids Res, 37:e45.
50.
Pfaffl MW. (2001). A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acid Res, 29:e45.
51.
Hsieh-LiHM, ChangJG, JongYJ, WuMH, WangNM, TsaiCH, LiH. (2000). A mouse model for spinal muscular atrophy. Nat Genet, 24:66–70.
52.
GogliottiRG, HammondSM, LutzC and Didonato.CJ (2010). Molecular and phenotypic reassessment of an infrequently used mouse model for spinal muscular atrophy. Biochem Biophys Res Commun, 391:517.
53.
ProkhorovaDV, ChelobanovBP, BurakovaEA, FokinaAA and StetsenkoDA. (2017). New oligodeoxyribonucleotide derivatives bearing internucleotide N-tosyl phosphoramidate groups: synthesis and complementary binding to DNA and RNA. Russ J Bioorg Chem, 43:38–42.
54.
SuY, FujiiH, BurakovaEA, ChelobanovBP, FujiiM, StetsenkoDA and FilichevVV. (2019). Neutral and negatively charged phosphate modifications altering thermal stability, kinetics of formation and monovalent ion dependence of DNA G-quadruplexes. Chem Asian J, 14:1212–1220.
55.
AkhtarS and JulianoRL. (1992). Cellular uptake and intracellular fate of antisense oligonucleotides. Trends Cell Biol, 2:139–144.
56.
JulianoRL, CarverK, CaoC and MingX. (2013). Receptors, endocytosis, and trafficking: the biological basis of targeted delivery of antisense and siRNA oligonucleotides. J Drug Target, 21:27–43.
57.
LiangXH, ShenW, SunH, KinbergerGA, PrakashTP, NicholsJG and CrookeST. (2016). Hsp90 protein interacts with phosphorothioate oligonucleotides containing hydrophobic 2′-modifications and enhances antisense activity. Nucleic Acids Res, 44:3892–3907.
58.
LiangXH, SunH, ShenW and CrookeST. (2015). Identification and characterization of intracellular proteins that bind oligonucleotides with phosphorothioate linkages. Nucleic Acids Res, 43:2927–2945.
59.
ShenW, LiangXH, SunH and CrookeST. (2015). 2′-Fluoro-modified phosphorothioate oligonucleotide can cause rapid degradation of P54nrb and PSF. Nucleic Acids Res, 43:4569–4578.
60.
ShengL, RigoF, BennettCF, KrainerAR and HuaY. (2020) Comparison of the efficacy of MOE and PMO modifications of systemic antisense oligonucleotides in a severe SMA mouse model. Nucleic Acids Res, 48:2853–2865.
61.
PatutinaOA, Gaponova MiroshnichenkoSK, Sen'kovaAV, SavinIA, GladkikhDV, BurakovaEA, FokinaAA, MaslovMA, Shmendel’EV, et al. (2020). Mesyl phosphoramidate backbone modified antisense oligonucleotides targeting miR-21 with enhanced in vivo therapeutic potency. Proc Natl Acad Sci U S A, 117:32370–32379.
62.
LeBT, AdamsAM, FletcherS, WiltonSD and VeeduRN. (2017). Rational design of short locked nucleic acid-modified 2′-O-methyl antisense oligonucleotides for efficient exon-skipping in vitro. Mol Ther Nucleic Acids, 9:155–161.
63.
HandeM, SaherO, LundinKE, SmithCIE, ZainR and LönnbergT. (2019). Oligonucleotide-palladacycle conjugates as splice-correcting agents. Molecules 24:. E1180.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
